8-K: NovaBay Undergoes Control Change, New CEO Appointed

NovaBay Pharmaceuticals announced a change of control with R01 Fund LP and Framework Ventures IV L.P. becoming majority owners, alongside a new CEO appointment and significant equity transactions.

Summary

• NovaBay Pharmaceuticals, Inc. experienced a change of control, with R01 Fund LP and Framework Ventures IV L.P. (the Purchasers) each acquiring 45.1% beneficial ownership, totaling 90.2% combined.
• The change of control resulted from a Securities Purchase Agreement (SPA) where former CEO David Elliot Lazar sold Series D Preferred Stock and assigned rights to Series E Preferred Stock to the Purchasers for an aggregate of $9,850,000.
• The company issued and sold pre-funded warrants to the Purchasers for an aggregate of 5,405,406 shares of common stock, generating approximately $6,000,000 in gross proceeds.
• Stockholders approved the conversion of 441,325 shares of Series D Preferred Stock into 77,000,000 common shares and 268,750 shares of Series E Preferred Stock into 43,000,000 common shares.
• David Elliot Lazar resigned as CEO and director, effective October 17, 2025, along with four other board members (Justin Hall, Julia Garlikov, Mijia (Bob) Wu, and Yongxiang (Sean) Zheng) effective October 16, 2025.
• Michael Kazley, Managing Member of R01 Fund LP, was appointed as the new Chief Executive Officer and Chairman of the Board, effective October 16, 2025.
• Stockholders approved a reverse stock split at a ratio between 1-for-2 and 1-for-10, with the exact ratio to be determined by the Board.
• The authorized number of common stock shares was increased from 150,000,000 to 1,500,000,000, while a proposal to increase authorized preferred stock from 5,000,000 to 10,000,000 failed.

Sentiment

Score: 3

Explanation: The filing details a significant change of control and a substantial equity issuance at what appears to be a low valuation, coupled with a planned reverse stock split, which often indicates underlying financial or market perception issues. While new capital is raised and new management is in place, the terms suggest a challenging situation for existing minority shareholders.

Positives

• Successful capital infusion of approximately $6,000,000 from pre-funded warrants.
• New leadership with Michael Kazley, who has extensive investment management experience, potentially bringing fresh strategic direction.
• Stockholder approval for the conversion of Series D and E Preferred Stock into common stock, simplifying the capital structure.
• Approval to increase authorized common stock, providing flexibility for future equity issuances or strategic moves.

Negatives

• Significant change of control (90.2% beneficial ownership by two entities) could lead to a highly concentrated ownership structure, potentially reducing influence for other shareholders.
• The reverse stock split, while approved, often signals a company's attempt to meet listing requirements or improve stock perception, which can sometimes be viewed negatively by the market.
• A proposal to increase authorized preferred stock failed, limiting flexibility in that class of equity.
• The issuance of pre-funded warrants at an effective price of approximately $1.11 per share (based on aggregate proceeds and shares) suggests a low valuation for new equity.

Risks

• Dilution: The conversion of Series D and E Preferred Stock into 120,000,000 common shares, plus the 5,405,406 shares from pre-funded warrants, represents significant potential dilution for existing common stockholders.
• Concentrated Ownership: R01 Fund LP and Framework Ventures IV L.P. now beneficially own 90.2% of outstanding common stock, which could lead to decisions primarily benefiting these two entities.
• Reverse Stock Split Impact: While intended to improve stock price, reverse splits can sometimes lead to further price declines or reduced liquidity.
• Transfer Restrictions: Securities are subject to restrictions on transferability and resale, requiring an effective registration statement or exemption.
• Indefinite Investment Period: Investors may be required to bear the financial risks of this investment for an indefinite period of time.

Future Outlook

The Board intends to consider candidates to fill the four current vacancies on the Board of Directors in due course. The exact ratio and timing of the approved reverse stock split will be determined by the Board and provided in subsequent disclosures. The pre-funded warrants will be exercisable starting January 1, 2026.

Management Comments

• The Company believes that Michael Kazley is qualified to serve on the Board because of his extensive experience in investment management and the digital asset markets.

Industry Context

The significant equity infusion and change of control suggest a strategic pivot or recapitalization effort, potentially aimed at strengthening the company's financial position or pursuing new growth avenues. The appointment of a CEO with a background in investment management and digital assets could signal a shift in strategic focus or a move towards more aggressive capital deployment, which is common in evolving biotech or pharma sectors seeking new funding or market opportunities.

Management Changes

Corporate Governance

Related Party Transactions

• David Elliot Lazar, the former Chief Executive Officer and director, entered into a Securities Purchase Agreement with R01 Fund LP and Framework Ventures IV L.P. to sell his Series D Preferred Stock and assign rights to Series E Preferred Stock for $9,850,000.
• Michael Kazley, the newly appointed CEO and Chairman of the Board, is also the Managing Member and General Partner of R01 Fund LP, one of the Purchasers involved in the change of control and equity issuance.
• Equity consideration with an aggregate value of $40,000 was approved for payment to resigning non-employee directors.

Stakeholder Impact

• Shareholders: Significant dilution from preferred stock conversions and warrant exercises. Change of control to two major investors (90.2% beneficial ownership) could reduce influence for minority shareholders. Potential impact from reverse stock split.
• Management/Employees: New CEO and Chairman appointed, significant board changes. Potential for strategic shifts under new leadership.
• Creditors: Capital raise provides additional funds, potentially improving financial stability.

Next Steps

• The Board intends to consider candidates to fill the four current vacancies on the Board of Directors.
• The Board will determine the exact ratio and timing of the reverse stock split, with additional details to be provided in subsequent disclosures.
• The Series D Preferred Stock will automatically convert into common stock three business days after October 16, 2025.
• The Series E Preferred Stock will convert at the option of the holder or automatically convert 30 business days after October 16, 2025.
• The Pre-Funded Warrants will become exercisable on or after January 1, 2026.

Key Dates

Recommendation

The filing indicates a distressed situation for NovaBay Pharmaceuticals. A change of control where two entities acquire over 90% beneficial ownership, coupled with a substantial equity issuance at a low effective price and the approval of a reverse stock split, suggests significant underlying challenges. While new capital and leadership are in place, the terms of these transactions are highly dilutive and concentrate power, which is generally unfavorable for existing minority shareholders. The failure to approve an increase in authorized preferred stock also points to potential governance issues or limitations. Investors should consider selling given the significant dilution, loss of control, and the implications of a reverse stock split.

Keywords

NovaBay Pharmaceuticals, NBY, SEC Filing, 8-K, Change of Control, Equity Issuance, Pre-Funded Warrants, Series D Preferred Stock, Series E Preferred Stock, Reverse Stock Split, Management Change, CEO Appointment, Michael Kazley, David Lazar, R01 Fund LP, Framework Ventures IV L.P., Stockholder Approval, Corporate Governance, Authorized Shares